As things currently stand a reduction in new cases
Post# of 148187
What the future holds with the addition of leronlimab. With viral rates as low as .4 copies per ml on leronlimab transmission rates should be further reduced. No drug resistance. Extended coverage for any lapse in drug usage.
This will not be the elimination of HIV due to CXCR5 variant and other factors. But leronlimab can produce a dramatic reduction in new cases and a better quality of life for existing cases.
Leronlimab is a game changer and that will eventually be reflected in the share price.